So, so happy for you all at One Biosciences! 💫 Your €15M Series A marks a strong vote of confidence in your vision and the platform you're building to bring single-cell technologies into the clinic. As you move forward with bringing OneMap™ into the clinic and deepening partnerships with pharma and biotech companies, know that we’re here to support you. Connecting startups with the right players is at the heart of what we do at BioLabs, and we’re always glad to explore the right opportunities alongside you. Can’t wait to see what’s next. 🙌 Hedi Ben Brahim
🎉 I am so happy and energized to share this major milestone for One Biosciences: we’ve just closed a €15M Series A to accelerate the clinical deployment of our AI-driven single-cell platform ! It’s a testament to the incredible work of the team, to the bold vision shaped by Céline, Magali and David and Home Biosciences, back in 2020, the trust of a growing ecosystem and the guidance from our board. I am so lucky to lead such a team and to have the opportunity to deliver such a project. The endorsement from leading clinicians is a powerful validation of our vision and approach. What’s ahead? → Bringing OneMap™ into the clinic → Deepening partnerships with and pharmaceutical companies and biotechs → Most importantly: bringing this tech to patients who deserve better answers A heartfelt thank you to our investors for their belief in our vision: Redmile Group and Blast Club, Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures and Kima Ventures. And to all those who advised, challenged, supported us along the way in a challenging environment: your guidance helped shape what One Biosciences is becoming. Now the real work begins ! #SeriesA #OneBiosciences #CancerDiagnostics #SingleCell #PrecisionOncology #AI #HealthTech